TABLE 5.
Factors associated with COVID-19 for patients with measurement of immune response after vaccination (n = 181).
| Variable | Univariate analysis | Cox regression | ||||
|---|---|---|---|---|---|---|
| Odds ratio (OR) | OR 95% CI | p-value | Hazard ratio (HR) | HR 95% CI | p-value | |
| Female | 0.98 | 0.51–1.92 | 0.9583 | |||
| Age | 0.98 | 0.95–1.01 | 0.117 | 1.00 | 0.97–1.02 | 0.8655 |
| Vaccine ≥3 doses | 0.35 | 0.14–0.86 | 0.0200 | 0.52 | 0.27–1.11 | 0.0714 |
| Transplant duration | 1.00 | 0.99–1.00 | 0.0334 | 1.00 | 0.99–1.00 | 0.2446 |
| Creatinine level | 1.03 | 0.61–1.59 | 0.8968 | |||
| Tacrolimus | 1.03 | 0.82–1.28 | 0.8018 | |||
| mTOR inhibitor use | 0.67 | 0.35–1.30 | 0.2372 | 0.82 | 0.46–1.47 | 0.5036 |
| MMF | 0.99 | 0.50–1.94 | 0.9733 | |||
| Steroid | 1.15 | 1.02–1.32 | 0.0290 | 1.08 | 0.96–1.19 | 0.1605 |
| Hypertension | 0.89 | 0.45–1.79 | 0.7401 | |||
| Diabetes | 1.47 | 0.67–3.13 | 0.3221 | 1.62 | 0.80–3.12 | 0.1635 |
| Antibody titer ≥1,689.3 BAU/mL | 0.36 | 0.16–0.72 | 0.0058 | 0.46 | 0.21–0.95 | 0.0412 |
| Positive IGRA | 0.60 | 0.30–1.17 | 0.1409 | 1.29 | 0.63–2.55 | 0.4647 |
CI, confidence interval; MMF, mycophenolate mofetil; BAU, binding antibody unit; IGRA, interferon-γ release assay.